Department of Radiology, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan.
Cardiovasc Intervent Radiol. 2012 Apr;35(2):399-405. doi: 10.1007/s00270-011-0172-4. Epub 2011 May 17.
This study was designed to evaluate the anti-tumor effects of miriplatin-lipidol and fine-powder cisplatin-lipiodol suspensions.
Assessment of the cytotoxicity of two drugs was performed: a soluble derivative of miriplatin (DPC) and fine-powder cisplatin. We randomly divided 15 rabbits with transplanted VX2 liver tumors into three equal groups. They were infused via the proper hepatic artery with a miriplatin-lipiodol suspension (ML), a fine-powder cisplatin-lipiodol suspension (CL), or saline (control) and the tumor growth rate was determined on MR images acquired before and 7 days after treatment. The concentration of platinum (PCs) in blood was assayed immediately, and 10, 30, and 60 min, and 24 h and 7 days after drug administration. Its concentration in tumor and surrounding normal liver tissues was determined at 7 days postadministration.
At high concentrations, fine-powder cisplatin exhibited stronger cytotoxicity than DPC. At low concentrations, both agents manifested weak cytotoxicity. While there was no difference between the tumor growth rate of the ML and the CL groups, the difference between the controls and ML- and CL-treated rabbits was significant. The blood PCs peaked at 10 min and then gradually decreased over time. On the other hand, no platinum was detected at any point after the administration of ML. There was no difference between the ML and CL groups in the PCs in tumor tissues; however, in normal hepatic tissue, the PCs were higher in ML- than CL-treated rabbits.
We confirmed the anti-tumor effect of ML and CL. There was no significant difference between the anti-tumor effect of ML and CL at 7 days postadministration.
本研究旨在评估米立铂脂质体和细粉顺铂脂质体混悬剂的抗肿瘤作用。
评估两种药物的细胞毒性：可溶性米立铂衍生物（DPC）和细粉顺铂。我们将 15 只荷 VX2 肝癌兔随机分为三组，分别经肝固有动脉注入米立铂脂质体混悬剂（ML）、细粉顺铂脂质体混悬剂（CL）或生理盐水（对照组），并在治疗前和治疗后 7 天进行 MR 成像，以确定肿瘤生长率。在给药后立即、10、30、60 分钟和 24 小时及 7 天，检测血中铂浓度（PCs），并在给药后 7 天检测肿瘤和周围正常肝组织中的铂浓度。
高浓度时，细粉顺铂的细胞毒性强于 DPC，低浓度时两者均表现出弱的细胞毒性。ML 和 CL 组的肿瘤生长率无差异，但对照组与 ML 和 CL 处理组之间的差异有统计学意义。血中 PCs 在 10 分钟时达到峰值，然后随时间逐渐下降。另一方面，ML 给药后任何时间点均未检测到铂。肿瘤组织中 ML 和 CL 组的 PCs 无差异；然而，在正常肝组织中，ML 处理组的 PCs 高于 CL 处理组。
我们证实了 ML 和 CL 的抗肿瘤作用。给药后 7 天，ML 和 CL 的抗肿瘤作用无显著差异。
